EA200500691A1 - ПРИМЕНЕНИЕ АГОНИСТА ПЕРОКСИСОМА ПРОЛИФЕРАТОР-АКТИВИРОВАННОГО РЕЦЕПТОРА АЛЬФА (PPARα) И МЕТФОРМИНА ДЛЯ СНИЖЕНИЯ УРОВНЯ ТРИГЛИЦЕРИДОВ В СЫВОРОТКЕ КРОВИ - Google Patents

ПРИМЕНЕНИЕ АГОНИСТА ПЕРОКСИСОМА ПРОЛИФЕРАТОР-АКТИВИРОВАННОГО РЕЦЕПТОРА АЛЬФА (PPARα) И МЕТФОРМИНА ДЛЯ СНИЖЕНИЯ УРОВНЯ ТРИГЛИЦЕРИДОВ В СЫВОРОТКЕ КРОВИ

Info

Publication number
EA200500691A1
EA200500691A1 EA200500691A EA200500691A EA200500691A1 EA 200500691 A1 EA200500691 A1 EA 200500691A1 EA 200500691 A EA200500691 A EA 200500691A EA 200500691 A EA200500691 A EA 200500691A EA 200500691 A1 EA200500691 A1 EA 200500691A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pparα
agonist
triglicerides
metformine
receptor
Prior art date
Application number
EA200500691A
Other languages
English (en)
Other versions
EA009772B1 (ru
Inventor
Жан-Луи Жюньен
Ален Эдгар
Эвелин Шапю
Original Assignee
Фурнье Лабораториз Аеленд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фурнье Лабораториз Аеленд Лимитед filed Critical Фурнье Лабораториз Аеленд Лимитед
Publication of EA200500691A1 publication Critical patent/EA200500691A1/ru
Publication of EA009772B1 publication Critical patent/EA009772B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к комбинированному применению агониста PPARα и метформина для снижения уровня триглицеридов в сыворотке.Отчет о международном поиске был опубликован 2005.02.24.
EA200500691A 2002-11-28 2003-11-26 ПРИМЕНЕНИЕ КОМБИНАЦИИ АГОНИСТА ПЕРОКСИСОМА ПРОЛИФЕРАТОР-АКТИВИРОВАННОГО РЕЦЕПТОРА АЛЬФА (PPARα), МЕТФОРМИНА И ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОГО НОСИТЕЛЯ ДЛЯ ПРОИЗВОДСТВА ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ И СПОСОБ ЛЕЧЕНИЯ ОЖИРЕНИЯ EA009772B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02292940A EP1424070A1 (en) 2002-11-28 2002-11-28 Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
PCT/EP2003/013302 WO2004047831A2 (en) 2002-11-28 2003-11-26 Use of a pparalpha agonist and metformin for decreasing the serum triglycerides

Publications (2)

Publication Number Publication Date
EA200500691A1 true EA200500691A1 (ru) 2005-12-29
EA009772B1 EA009772B1 (ru) 2008-04-28

Family

ID=32241358

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500691A EA009772B1 (ru) 2002-11-28 2003-11-26 ПРИМЕНЕНИЕ КОМБИНАЦИИ АГОНИСТА ПЕРОКСИСОМА ПРОЛИФЕРАТОР-АКТИВИРОВАННОГО РЕЦЕПТОРА АЛЬФА (PPARα), МЕТФОРМИНА И ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОГО НОСИТЕЛЯ ДЛЯ ПРОИЗВОДСТВА ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ И СПОСОБ ЛЕЧЕНИЯ ОЖИРЕНИЯ

Country Status (22)

Country Link
US (2) US20060142397A1 (ru)
EP (2) EP1424070A1 (ru)
JP (1) JP2006508995A (ru)
CN (1) CN1777417B (ru)
AT (1) ATE362362T1 (ru)
AU (1) AU2003288175B2 (ru)
BR (1) BR0316810A (ru)
CA (1) CA2507894C (ru)
CY (1) CY1106749T1 (ru)
DE (1) DE60313886T2 (ru)
DK (1) DK1569634T3 (ru)
EA (1) EA009772B1 (ru)
ES (1) ES2287546T3 (ru)
HK (1) HK1077755A1 (ru)
MA (1) MA27553A1 (ru)
MX (1) MXPA05005707A (ru)
NO (1) NO20052549L (ru)
PT (1) PT1569634E (ru)
SI (1) SI1569634T1 (ru)
TN (1) TNSN05148A1 (ru)
WO (1) WO2004047831A2 (ru)
ZA (1) ZA200504345B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
WO2010132580A2 (en) * 2009-05-12 2010-11-18 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2011159917A2 (en) 2010-06-16 2011-12-22 The Administrators Of The Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
CN111374093A (zh) * 2018-12-28 2020-07-07 高倩 超级肥胖小鼠的构建与鉴定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) * 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2275199A1 (fr) * 1974-06-19 1976-01-16 Cerpha (chloro-4 phenoxy) isobutyrate de dimethylbiguanide, son procede de preparation et medicaments contenant ce produit comme principe actif
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
DE69733154T2 (de) * 1996-02-02 2006-03-09 Merck & Co., Inc. Verfahren zur behandlung von diabetes und verwandter krankheitszustände.
EP0930882A2 (en) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US5942500A (en) * 1998-04-27 1999-08-24 Perry; Stephen C. Dietary composition to reduce dietary fats
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6498193B2 (en) * 1999-12-22 2002-12-24 Trustees Of Dartmouth College Treatment for complications of type 2 diabetes
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
AU2003296895A1 (en) * 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites

Also Published As

Publication number Publication date
TNSN05148A1 (fr) 2007-05-14
WO2004047831A3 (en) 2005-02-24
EP1569634B8 (en) 2007-08-29
US20100144874A1 (en) 2010-06-10
MA27553A1 (fr) 2005-10-03
AU2003288175B2 (en) 2008-11-13
DK1569634T3 (da) 2007-09-10
JP2006508995A (ja) 2006-03-16
DE60313886T2 (de) 2008-01-17
ES2287546T3 (es) 2007-12-16
WO2004047831A2 (en) 2004-06-10
EP1569634A2 (en) 2005-09-07
US20060142397A1 (en) 2006-06-29
CN1777417B (zh) 2010-10-06
CA2507894A1 (en) 2004-06-10
CN1777417A (zh) 2006-05-24
EP1569634B1 (en) 2007-05-16
SI1569634T1 (sl) 2007-10-31
CY1106749T1 (el) 2012-05-23
CA2507894C (en) 2011-01-04
EP1424070A1 (en) 2004-06-02
EA009772B1 (ru) 2008-04-28
ATE362362T1 (de) 2007-06-15
MXPA05005707A (es) 2005-07-26
DE60313886D1 (de) 2007-06-28
PT1569634E (pt) 2007-08-22
NO20052549L (no) 2005-06-10
HK1077755A1 (en) 2006-02-24
AU2003288175A1 (en) 2004-06-18
ZA200504345B (en) 2006-08-30
BR0316810A (pt) 2005-10-18

Similar Documents

Publication Publication Date Title
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
EA200500691A1 (ru) ПРИМЕНЕНИЕ АГОНИСТА ПЕРОКСИСОМА ПРОЛИФЕРАТОР-АКТИВИРОВАННОГО РЕЦЕПТОРА АЛЬФА (PPARα) И МЕТФОРМИНА ДЛЯ СНИЖЕНИЯ УРОВНЯ ТРИГЛИЦЕРИДОВ В СЫВОРОТКЕ КРОВИ
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200300036A1 (ru) Комбинации ингибиторов дипептидилпептидазы iv и других антидиабетических агентов для лечения сахарного диабета
EA200700108A1 (ru) Новое применение пептидных соединений для лечения идиопатического тремора и других синдромов, ассоциированных с тремором
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
CY1109523T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
CR8932A (es) Composicion de anticuerpo her2
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
EA200500146A1 (ru) Моноэтансульфонат 3-z-[1-4-(n-((4-метилпиперазин-1-ил)метилкарбонил)-n-метиламино)анилино)-1-фенилметилен]-6-метоксикарбонил-2-индолинона и его применение в составе фармацевтической композиции
AR015358A1 (es) Antagonistas de la endotelina: n-[[2'-[[(4,5-dimetil-3-isoxazolil)amino]sulfonil]-4-(2-oxazolil)[1,1'-bifenil]-2-il]metil]-n,3,3-trimetilbutanamida yn-(4,5-demitil-3-isoxazolil)-2'-[(3,3-dimetil-2-oxo-1-pirrolidinil)metil]-4'-(2-oxazolil)[1,1'-bifenil]-2-sulfonamida y sales de los mismos y las compo
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
EA200602220A1 (ru) Новое применение пептидных соединений для лечения амиотрофического бокового склероза
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
EA200101089A1 (ru) Новый способ лечения
EA200401301A1 (ru) Полициклические соединения как эффективные антагонисты альфа-2 адренорецептора
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ RU